Drug intelligence / Profile preview

EPAspire

Development stage: Phase 3
Lead developer: SLA Pharma
Modality: Small Molecules
Administration: Oral

Overview

**EPAspire** is a novel oral pharmaceutical formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA, 99% purity) delivered in gastro-resistant capsules for optimal pH-dependent absorption in the gut. Developed by KD Pharma Group and SLA Pharma, it modulates inflammation by incorporating into cell membranes to suppress pro-inflammatory mediators like IL-6 and leukotriene B4 while generating pro-resolving mediators that enhance microbial killing and organ protection, without broadly suppressing immune responses. Primarily indicated for familial adenomatous polyposis (FAP), an orphan disease, it has shown potential in reducing inflammatory cytokine expression relevant to conditions like COVID-19 and ulcerative colitis.[1][2][9]

Brand names: EPAspire
Other names: Alfa

Beyond the preview

Go deeper on EPAspire.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPAspire.

Explore the full profile